• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board

    3/3/23 4:30:00 PM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email

    SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023.

    Quest Diagnostics Incorporated logo. (PRNewsFoto/Quest Diagnostics Incorporated)

    "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute Quest Diagnostics' strategy," said Tim Ring, Quest's Lead Independent Director.

    Mr. Davis, who joined the company in 2013 and assumed the role of Chief Executive Officer, President and Director on November 1, 2022, will succeed former CEO Steve Rusckowski, who remains Chairman through March 31, 2023.  

    "I am honored to assume these additional responsibilities as I continue to work together with the Board, Quest's nearly 50,000 colleagues and our many customers and partners to create a healthier world and build value," said Mr. Davis.  "I want to thank Steve for his many years of stewardship as Chairman and CEO. I look forward to building on his contributions and working closely with Tim Ring in my new capacity as Chairman."

    Mr. Ring added: "On behalf of the full Board, I want to thank Steve Rusckowski for his leadership over the past decade and his tremendous dedication and commitment to making Quest Diagnostics the exceptional company it is today."

    Jim Davis Biography

    Jim Davis is Chief Executive Officer and President of Quest Diagnostics, a role he assumed on November 1, 2022, after a gradual leadership transition plan, succeeding Quest's long-time CEO Steve Rusckowski.

    Previously, Jim served as Executive Vice President for General Diagnostics since 2017. Jim joined Quest in April 2013 as Senior Vice President, Diagnostic Services and was named Senior Vice President, Operations in February 2014.

    Before joining Quest, Jim served as CEO of InSightec, Inc., a medical device company. Prior to that, he held senior management positions in a two-decade career in General Electric's aviation and healthcare businesses, including leading GE's MRI business for five years. Before GE, Jim led the development of strategic and operating initiatives for clients of McKinsey & Company, Inc. He holds a master's degree in management from the Sloan School of Management at Massachusetts Institute of Technology, a master's degree in science from MIT and a bachelor's degree in aeronautical engineering from the University of Michigan.

    Steve Rusckowski Biography

    Steve Rusckowski joined Quest Diagnostics as Chief Executive Officer in May 2012. At that time Quest was not growing, and he led the transformation of the company into the leader in diagnostic information services with strong financial performance. Steve focused Quest on accelerating growth and driving operational excellence by improving relationships with health plans and hospital health systems and expanding faster-growing businesses in advanced diagnostics and consumer testing.

    Steve also drove Quest to be more inclusive. Today the company is overseen by a board of directors that is made up of 40% women and two people of color. In 2020, Mr. Rusckowski spearheaded the launch of Quest for Health Equity, a $100 million commitment to reduce health disparities among the underserved in the U.S.

    At the outset of the COVID-19 pandemic, Steve became deeply involved in the national response, partnering with elected officials and public health authorities, as well as healthcare providers, payers and retailers, to quickly expand access to COVID-19 testing.

    Prior to joining Quest Diagnostics, Steve was CEO of Philips Healthcare, which became the largest unit of Royal Philips Electronics under his leadership. He joined Philips in 2001 when it acquired the Healthcare Solutions Group he was leading at Hewlett-Packard/Agilent Technologies.

    Steve served as Chairman of the Board of Directors of the American Clinical Laboratory Association from 2014 to 2017. He is also an Emeritus Director of Project Hope, a global health education and humanitarian assistance organization. He earned a Master of Science degree in Management from the Sloan School of Management at Massachusetts Institute of Technology and a Bachelor of Science degree in Mechanical Engineering from Worcester Polytechnic Institute, where he serves on the Board of Trustees.

    About Quest Diagnostics 

    Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.  Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-board-of-directors-elects-james-e-davis-chairman-of-the-board-301762477.html

    SOURCE Quest Diagnostics

    Get the next $DGX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    8/28/2024$165.00In-line
    Evercore ISI
    7/10/2024$145.00 → $165.00Neutral → Buy
    Citigroup
    More analyst ratings

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

    Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

    4/2/25 8:51:11 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics downgraded by Citigroup with a new price target

    Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00

    3/4/25 7:20:57 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Quest Diagnostics from Market Perform to Outperform and set a new price target of $174.00 from $169.00 previously

    1/6/25 7:49:06 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Clinical Solutions Kuppusamy Karthik covered exercise/tax liability with 123 shares, decreasing direct ownership by 1% to 8,338 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/15/25 5:25:57 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP for Diagnostic Services Plewman Patrick sold $968,625 worth of shares (5,535 units at $175.00) and exercised 3,560 shares at a strike of $86.63, decreasing direct ownership by 9% to 19,219 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/8/25 4:40:39 PM ET
    $DGX
    Medical Specialities
    Health Care

    SVP, Clinical Solutions Kuppusamy Karthik exercised 8,269 shares at a strike of $102.77 and sold $1,759,931 worth of shares (10,479 units at $167.95), decreasing direct ownership by 21% to 8,450 units (SEC Form 4)

    4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

    8/1/25 4:37:46 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference

    SECAUCUS, N.J., Aug. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2025 Global Healthcare Conference in New York City on Wednesday, September 10, 2025, at 10:50 a.m. Eastern Time. The fireside chat and Q&A session will be webcast live during the conference on the company's investor relations page, which can be accessed at ir.QuestDiagnostics.com.

    8/15/25 6:14:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J., Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October 20, 2025 to shareholders of record of Quest Diagnostics common stock on October 3, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to ta

    8/13/25 6:35:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types

    SECAUCUS, N.J. and BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE:DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for head and neck and advanced cutaneous oncology. The research collaboration will investigate the use of Haystack MRD™, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease test, as an aid in postoperative therapy decisions for two cancer types: cutaneous squamous cell carcinoma (CSCC), a type of skin cancer, and HPV-independent head and neck squamous cell carcinoma (HNSCC).

    8/7/25 9:08:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Quest Diagnostics Incorporated

    SCHEDULE 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    8/14/25 1:07:20 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Quest Diagnostics Incorporated

    10-Q - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    7/23/25 4:25:08 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

    7/22/25 6:48:39 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Financials

    Live finance-specific insights

    View All

    Quest Diagnostics Declares Quarterly Cash Dividend

    SECAUCUS, N.J., Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October 20, 2025 to shareholders of record of Quest Diagnostics common stock on October 3, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to ta

    8/13/25 6:35:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

    Second quarter revenues of $2.76 billion, up 15.2% from 2024Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024Year-to-date cash provided by operations of $858 million, up 67.1% from 2024Full year 2025 reported diluted EPS now expected to be between $8.60 and $8.80; and adjusted diluted EPS is expected to be between $9.63 and $9.83SECAUCUS, N.J., July 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2025.

    7/22/25 6:47:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025

    SECAUCUS, N.J., June 23, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial results on Tuesday, July 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.Q

    6/23/25 10:52:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/13/24 5:12:21 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    1/25/24 12:16:40 PM ET
    $DGX
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

    SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

    2/7/23 1:25:52 PM ET
    $DGX
    Medical Specialities
    Health Care

    $DGX
    Leadership Updates

    Live Leadership Updates

    View All

    Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

    Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

    1/17/24 8:58:00 AM ET
    $DGX
    Medical Specialities
    Health Care

    Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board

    SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute

    3/3/23 4:30:00 PM ET
    $DGX
    Medical Specialities
    Health Care

    Quotient Limited Announces Appointment of Chief Financial Officer

    JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end. "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I w

    10/12/21 8:45:00 AM ET
    $DGX
    $QTNT
    Medical Specialities
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances